Once inside the cell, miR-105 binds to the myelocytomatosis oncogene (MYC) negative regulator, MXI1, activating MYC signaling and promoting the expression of genes related to glucose (HK2, LDHA, LDHB) and glutamine (GLS) metabolism and for metabolite transportation (SLC2A1, SLC16A1, SLC16A3, and SLC1A5) converting CAFs into an energy source for cancer cells in the TME (57). Here, MYC is linked to cancer.